I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Vice President of Pharmacovigilance - Pharmacovigilance

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA$330k - $410k /yrRemote

About the Job

Requirements

  • An MD is required, with clinical and industry experience and a proven track record leading pharmacovigilance teams.
  • At least 15 years of experience in drug safety and pharmacovigilance roles in the biotechnology or pharmaceutical industry is required.
  • A proven leadership track record building and leading high-performing teams is required.
  • In-depth knowledge of global pharmacovigilance regulations and compliance requirements, including EMA, FDA, and ICH requirements, is required.

Responsibilities

  • Develop and implement pharmacovigilance processes, policies, standard operating procedures, and safety database and pharmacovigilance systems.
  • Lead cross-functional governance, benefit-risk assessment, signal detection, and risk management efforts.
  • Chair the executive safety review committee, oversee safety data exchange with partners, and contribute to industry-wide safety initiatives.
  • Partner with clinical development to integrate safety into protocols, risk management plans, and safety charters.
  • Provide pharmacovigilance oversight for regulatory filings, including IND, BLA, and MAA filings; oversee Clinical Overviews, ISS, and RMPs; review IBs, DSURs, and key CSR sections; and participate in regulatory meetings as needed.
  • Lead medical review of individual case safety reports and oversee pharmacovigilance team operations, quality, and compliance with global safety regulations.
  • Monitor and assess contract research organization performance on pharmacovigilance activities.
  • Recruit, hire, train, mentor, and coach pharmacovigilance staff, and oversee project deliverables and performance evaluations.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs